Alcon (ALC) is quietly showing major strength as the monthly chart below shows and Fibonacci extension targets at $101.25 and $109 now in focus. In reviewing the latest quarter, Alcon is winning market share and launching a lot of new products which sets up for strong growth in 2025. Shares are not cheap at 18.6X EBITDA, 41st percentile of its 10-year average, but offers solid 6-8% annual revenue growth and 12-15% EPS growth. ALC also did an interesting acquisition of BELKIN Vision which offers a new opportunity in the glaucoma market and it continues to expand its presence in China.